Population pharmacokinetics of teicoplanin in infants and children

• Published in: Japanese Journal of Chemotherapy Vol. 55; no. 1; pp. 17 - 22
• Main Authors: Ishii, Masahiro, Arima, Misayo, Sunakawa, Keisuke, Kobayashi, Masahiro, Kimura, Toshimi, Yago, Kazuo
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 01.01.2007; 公益社団法人 日本化学療法学会
• Subjects: child; NONMEM; population pharmacokinetics; teicoplanin
• ISSN: 1340-7007; 1884-5886
• DOI: 10.11250/chemotherapy1995.55.17

We analyzed teicoplanin (TEIC) pharmacokinetics in infants and children using the nonlinear mixed effects model (NONMEM) to estimate population pharmacokinetics parameters. Subjects were 63 children (28 days to 16 years old) prescribed TEIC at Kitasato University Hospital and undergoing therapeutic drug monitoring. Population pharmacokinetics parameters were calculated using 1-compartment model of clearance (CLTEIC) and volume of distribution (VdTEIC). An exponential error model was used to determine interindividual variability and a relative error model for residual variability. Patient age, gender, weight, serum creatinine, and serum albumin were covariates. The observed TEIC serum concentration was 101 points ranging from 4.4-39.1ug/mL. TEIC population pharmacokinetics parameters finally estimated were: CLTEIC=0.00836×(wt/Scr) 0786 (L/h) and VdTEIC=0.8× wt (L). Interindividual variability was CLTEIC=26.7 (%) and VdTEIC=32.7 (%), and residual variability was 2.8, μg/mL. CLTEIC changes due to aging correlated well with that of kidney gravity. Model validity was sufficient. Our reports suggest that the population parameters are useful in evaluating TEIC pharmacokinetics in children undergoing long-term hospitalization.